Straightline Group’s AbbVie ABBV Stock Holding History

Straightline Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,360	Closed	-$242K	–	15
2024 Q4	$242K	Buy	+1,360	New	+$250K	0.16%	38

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Straightline Group's ABBV Position: Q1 2025 in Review

Straightline Group sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 1,360 shares — an estimated $242K sold.

Straightline Group first reported a position in ABBV in Q4 2024 and held it in 1 quarter. The position peaked at $242K in Q4 2024. 3,820 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

Straightline Group reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
Straightline Group sold 1,360 AbbVie shares in Q1 2025, an estimated $242K.
Straightline Group first reported a position in AbbVie in Q4 2024 and held it in 1 quarter.
Straightline Group's AbbVie position peaked at $242K in Q4 2024.
3,820 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Straightline Group's 13F filing for Q1 2025, filed 14 May 2025.